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Abstract 
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is developing 
guidelines for allergen immunotherapy (AIT) for the management of allergic rhinitis, allergic asthma, IgE-
mediated food allergy and venom allergy. To inform the development of clinical recommendations, we 
undertook systematic reviews to critically assess evidence on the effectiveness, safety and cost-
effectiveness of AIT for these conditions. This paper focusses on synthesizing data and gaps in the 
evidence on the cost-effectiveness of AIT for these conditions. 
Methods: We produced summaries of evidence in each domain and then synthesized findings on health 
economic data identified from four recent systematic reviews on allergic rhinitis, asthma, food allergy and 
venom allergy, respectively.  The quality of these studies were independently assessed using the Critical 
Appraisal Skills Programme (CASP) tool for health economic evaluations.  
Results: 23 studies satisfied our inclusion criteria. Of these, 19 studies investigated the cost-effectiveness 
of AIT in allergic rhinitis, of which seven were based on data from randomized controlled trials with 
economic evaluations conducted from a health system perspective. This body of evidence suggested that 
sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT) would be considered cost-
effective using the (English) National Institute for Health and Clinical Excellence (NICE) cost-
effectiveness threshold of £20,000/quality adjusted life year (QALY). However, the quality of the studies 
and the general lack of attention to characterizing uncertainty and handling missing data should be taken 
into account when interpreting these results. For asthma, there were three eligible studies, all of which 
had significant methodological limitations; these suggested that SLIT, when used in patients with both 
asthma and allergic rhinitis, may be cost-effective with an incremental cost-effectiveness ratio (ICER) of 
£10,726 per QALY. We found one economic modelling study for venom allergy which, despite being 
based largely on expert opinion and plausible assumptions, suggested that AIT for bee and wasp venom 
allergy is only likely to be cost-effective for very high risk groups who may be exposed to multiple 
exposures to venom/year (e.g., bee keepers).  We found no eligible studies investigating the cost-
effectiveness of AIT for food allergy.  A
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Conclusions: Overall the evidence to support the cost-effectiveness of AIT is limited and of low 
methodological quality, but suggests that AIT may be cost-effective for people with allergic rhinitis with 
or without asthma and in high risk subgroups for venom allergy. We were unable to draw any conclusions 
on the cost-effectiveness of AIT for food allergy.  
 
Keywords: allergy; cost-effectiveness; immunotherapy; payer; quality adjusted life year 
 
Background 
Allergen immunotherapy (AIT) is a potential treatment option in those with severe and/or potentially 
life-threatening allergic disorders who are inadequately managed with pharmacotherapy. AIT is most 
relevant n relation to the management of allergic rhinitis, asthma, food allergy and venom allergy and it is 
for this reason that the European Academy of Allergy and Clinical Immunology (EAACI) is in the 
process of producing clinical practice guidelines for these conditions. 
 
We have recently completed systematic reviews investigating the role of AIT in the management of 
allergic rhinitis, asthma, food allergy and venom allergy focusing on the effectiveness, safety and cost-
effectiveness of AIT.1 2 3 4  During the course of undertaking these reviews, we identified a number of 
health economic evaluations, which we considered it prudent to synthesize with a view to drawing 
overarching insights into the state of this evidence-base and in order to guide future evaluations.   
 
Our specific aims were to: 
 Synthesize data on the cost-effectiveness of AIT for the clinical management of allergic rhinitis, 
allergic asthma, IgE-mediated food allergy and venom allergy from the perspective of health 
payers; and  
 Identify research gaps in relation to the cost-effectiveness of AIT for these conditions. 
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METHODS  
A detailed outline of the methods have previously been published in the protocols and papers of each 
individual review.i ii iii iv v vi vii viii We therefore confine ourselves to a synopsis of the methods employed.  
Search strategies 
Highly sensitive search strategies were developed, and validated study design filters were applied to 
retrieve articles pertaining to the use of AIT for allergic rhinitis, asthma, food allergy and venom allergy 
from electronic bibliographic databases.  The search strategies were developed on OVID MEDLINE and 
then adapted for the other databases.1-4 In all cases, the databases were searched from inception to 
October 31, 2015.  Additional papers were located through searching the references cited by the identified 
studies, and unpublished work and research in progress was identified through discussion with experts in 
the field.  There were no language restrictions employed.  
Study selection 
All references were uploaded into the systematic review software DistillerSR and duplicate records were 
removed.  Studies were independently checked by two reviewers (SD, MA, AaS) against the inclusion 
criteria detailed in the reviews.1-4 Any discrepancies were resolved through discussion and, when 
necessary, a third reviewer was consulted (AS).   
Quality assessment 
Quality assessments were independently carried out on each study by two reviewers (MA and SD).  The 
Critical Appraisal Skills Programme (CASP) Economic Evaluation Checklist for health economic studies 
was used for this purpose.ix Any discrepancies were resolved by discussion or arbitration by a third 
reviewer (AS). 
Data extraction, analysis and synthesis 
A data extraction sheet was developed to capture the pertinent features of the cost-effectiveness analysis 
based on the Drummond checklist and the National Institute for Health and Clinical Excellence (NICE) 
reference case for economic evaluations.x xi Data were independently extracted onto a customized data 
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extraction sheet developed for the purposes of these reviews by two reviewers (MA, AaS or SD) and any 
discrepancies were resolved by discussion or arbitration by a third reviewer (AS).  Where studies reported 
results from multiple perspectives, results from the health systems perspective were presented and where 
there were multiple outcome measures including quality adjusted life years (QALYs) the focus of the 
review was to present results in terms of QALYs. Costs were translated to 2014/15 GBP prices using 
National Health Service Personal Social Services Research Unit (NHS PSSRU) inflation indicesxii and 
standard exchange rates to aid the comparability of the studies. 
A detailed descriptive report was produced on each study to summarize the literature. This data extraction 
process was used to assess the methodological features of the applied economic evaluations and highlight 
key methodological gaps in the studies from a health economics perspective. The summary tables are 
reproduced in the results section of this article, with full data extraction forms available in Appendix 1. 
Registration and reporting 
The underpinning reviews have been registered with the International Prospective Register of Systematic 
Reviews (PROSPERO): Allergic Rhinitis: CRD42016035373; Allergic Asthma: CRD42016035372; 
Venom: CRD42016035374; Food Allergy: CRD42016039384.  The Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) checklist was used to guide the reporting of the 
systematic review (Appendix 2). 
 
RESULTS 
Overall description 
Our searches yielded 21 studies assessing the cost-effectiveness of allergic rhinitis, asthma and venom 
allergy that met our inclusion criteria (see Table 1 and Appendix 1). Two of these studies are included 
separately in both the asthma and rhinitis analyses. Nineteen studies focussed on allergic 
rhinitis,xiii,xiv,xv,xvi,xvii,xviii,xix,xx,xxi,xxii,xxiii, xxiv,xxv,xxvi,xxvii,xxviii,xxix,xxx,xxxi three on asthma13,14,xxxii and one on venom 
allergy.xxxiii No studies were identified investigating the cost-effectiveness of food allergy. We identified A
cc
ep
te
d 
A
rt
ic
le
A
cc
ep
te
d 
A
rt
ic
le
 
 
 
 
 
 
  
 
 
 
 
 
 
This article is protected by copyright. All rights reserved. 
studies looking at both sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT), and 
which included both children and adults.  
 
Quality assessment 
The overall quality of the studies was low. Of the 19 allergic rhinitis studies, nine were assessed to be of 
low quality,13,16-19,22,24,28,29 six medium15,20,21,23,25,30 and four high quality.14,26,27,30 Of the three asthma studies, 
two were of a low quality13,32 and one high quality.14 The one included venom allergy study was assessed 
to be of medium quality.33 The quality of the studies is summarized in Table 2a-e. 
 
Summary of evidence  
We begin by briefly summarizing the data in relation to each condition, and then synthesize findings 
across this body of evidence in order to highlight gaps and provide insights to inform the planning of 
future studies.  
 
Allergic rhinitis 
Of the 19 allergic rhinitis studies, two focussed on patients who all had both allergic rhinitis and allergic 
asthma 13,14 and the remaining 17 focussed on patients who had allergic rhinitis (some of whom also had 
asthma, but it was difficult to know how many because of lack of clarity in the descriptions of studies). 
Three of these studies reported results  from a societal perspective18,21,23 with the remaining 16 reporting 
information from a health systems perspective. 
Studies were based in a range of countries: Germany (N=7), Denmark (N=4), Italy (N=4), UK (N=4), 
Austria (N=2), Finland (N=2), France (N=2), Sweden (N=2), the Netherlands (N=2), Canada (N=1), 
Czech Republic (N=1), Norway (N=1) and Spain (N=1). Three studies reported including participants  
from more than one country.15,18,20  A
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Seven of the studies reported results against disease specific outcome measures whilst the remaining 
twelve reported results based on QALYs. A detailed summary of each study can be found in Table 1 and 
Appendix 1.  
 
Thirteen of the studies13-15,18-21,24-27,30,31 were based on randomized controlled trial (RCT) data or meta-
analyses of RCT data including two model-based evaluations.26,30 The remaining studies were based on a 
mixture of questionnaires, observational data and expert opinion. None of the studies based on non-
random data attempted to control for selection bias. None of the RCT-based studies described the 
amount of missing data in the study or explained how if at all any missing data was imputed for in the 
analyses. 
Study time horizons ranged between 1-15 years with the longer time horizon studies typically based on 
much shorter follow-up trial data (typically 1 year) and assuming constant continued treatment effects 
after AIT was discontinued. 
Nine of the studies13-16,18,25,26,28 compared SLIT with standard care; three studies17,20,26 compared SCIT 
with standard care; two studies23,29  compared AIT (undefined) versus standard care; seven studies 
19,21,22,24,26,30,31 compared SCIT versus SLIT, and two of these studies also compared different SLIT 
preparations.19,31 
 
There were seven studies based on RCT data conducted from a health system perspective and using 
QALYs as their outcome measure.  Two high quality studies were based in the UK. The first found that 
in patients with both rhinitis and asthma the incremental cost-effectiveness ratio (ICER) for SLIT versus 
standard care was £8,816 per QALY at 2005 prices inflated using NHS inflation indices (PSSRU) to 
£10,726 per QALY at 2014/15 prices.14 The second study found that in 5-16 year olds with 
rhinoconjuctivitis with or without asthma in the UK the ICER for SLIT versus standard care was £12,168 
per QALY at 2008 prices. Updating to 2014/15 prices this translated to an ICER of £13,357 per 
QALY.27  A
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Three studies were conducted in Germany in patients with rhinoconjunctivitis without asthma. The first 
medium quality study found the ICER for SLIT (Oralair) versus standard care was €14,728 per QALY at 
2011 prices. Converting to 2014/15 prices and GBP at 0.75 GBP per Euro translated this to an ICER of 
£11,460 per QALY.31 The remaining two studies were both of high quality. The second found the ICER 
for SLIT (Oralair) versus SCIT to be €12,593 per QALY at 2013 prices. Converting to 2014/15 prices 
and GBP at 0.75 GBP per Euro translated this to an ICER of £9,627 per QALY.30 The third German 
study found SCIT (Allergovit) to be cheaper and more effective than SLIT (Oralair). The ICER for SCIT 
(Allergovit) standard care was estimated to be €11,000 per QALY at 2013 prices. Converting to 2014/15 
prices and GBP at 0.75 GBP per Euro translated this to an ICER of £8,334 per QALY.26 
A medium quality study from Denmark looked at adult patients with rhinoconjuctivitis and found the 
ICER for SLIT versus standard care to be 134,105 DKK per QALY (no price year was given so we 
assumed the study was undertaken in the publication year i.e. 2008) updating to current prices and GBP 
at 0.1 GBP per DKK translated this to an ICER of £15,294 per QALY at 2014/15 prices.25 Finally a 
further medium quality study conducted in adult patients with rhinoconjuctivitis performed in the UK in 
which  ICERs for SCIT were calculated using healthcare data from Austria, Denmark, Finland, Germany, 
Sweden and the Netherlands. The ICERs of SCIT compared to standard care in 2005 Euro per QALY 
were 9716, 2586, 13683, 10300, 24519 and 22675, respectively. Updating to current prices and  at 0.75 
GBP per Euro gave ICERs of £8,866, £2,360, £12,486, £9,399, £22,374 and £20,691 per QALY 
respectively at 2014/15 prices.20  
It was unclear how comparable the patient populations were between the studies.  A particularly 
important factor that impacted on the costs and quality of life observed was the proportion of patients 
who also had asthma, but these proportions were not reported in many of the studies. The other 
interesting observation to be made is that the ICERs for AIT seemed to vary substantially between 
different health systems as demonstrated in Keiding et al 200720 where ICERs ranges from £2,360 per 
QALY in Denmark to £22,374 per QALY in the Netherlands suggesting that straightforward conclusions 
may not be generalizable even across seemingly similar countries. A
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In general, the studies find that AIT and where defined both SLIT and SCIT were more effective than 
standard care, but also more expensive. The studies that compared SLIT with SCIT gave mixed results 
not allowing us to conclude that either treatment is necessarily more effective or more costly than the 
other from a health system perspective. The studies comparing SLIT (Grazax) and SLIT (Oralair) 
suggested SLIT (Oralair) is both more effective and cheaper than SLIT (Grazax).19,31 
The seven RCT studies compared, disregarding the caveats about generalizability, suggested that SLIT 
and SCIT treatment would be considered cost-effective in this patient population in England at the 
standard NICE cost-effectiveness threshold of £20,000 per QALY. However, the quality of the studies 
and the general lack of attention to characterizing uncertainty and handling missing data should be taken 
into account when interpreting these results.  
 
Asthma 
Three studies were deemed suitable for use in the review of AIT to treat patients with allergic asthma. 
Data extraction of these studies is summarized in Table 1.  
Of the three health economic studies included, only one low quality study focussed on patients with 
allergic asthma without reported rhinitis.32 This was carried out in Germany and compared SCIT with 
standard care based on a small scale RCT (N=65) with three years of follow-up data. The study used a 
disease specific outcome measure (mean morning peak flow) with no attempt to convert it to a general 
quality of life measure such as QALYs making it impossible to assess the cost-effectiveness of the 
treatment. The study found that over the three years SCIT was more expensive than standard care and 
performed better than standard care on the disease specific outcome measure. 
The remaining two studies looked at people with both allergic rhinitis and asthma. The first of these 
compared SLIT with standard care in a RCT (N=151) conducted in the UK, Germany, Holland, 
Denmark, Sweden, Spain, Austria and Italy with results evaluated from an English NHS perspective.14 
This trial, which was already discussed in the rhinitis section above, used one year of treatment data and 
assumed a constant treatment effect over the three-year treatment period and the six years following the A
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end of the treatment, thereby extrapolating the treatment effect over years 2-9. EQ5D was used to 
evaluate the treatment outcome and the ICER of SLIT as compared to standard care at 2005 prices was 
calculated as £8,816 per QALY over the nine year period. The study did not attempt to characterize the 
uncertainty around this estimate. Updating this to 2014/15 prices using NHS PSSRU inflation indices 
translated this to an ICER of £10,726 per QALY.  
The final study, also in patients with rhinitis and asthma, based on a RCT (N=70) with five years of 
follow-up conducted in Italy compared SLIT with standard care and found that patients on SLIT cost less 
and suffered less symptoms than those on standard care.13 Methods of the study were not presented in 
enough detail to understand the analysis that had been performed and there was no attempt to convert 
the symptom score reported in the study to a general quality of life scale making it impossible to 
undertake a formal assessment of cost-effectiveness. 
From the very limited set of studies found, all of which had significant methodological limitations, we can 
conclude that there is a suggestion that SLIT when used in patients with both allergic asthma and allergic 
rhinitis may be cost-effective from an English NHS perspective with an ICER of £10,726 per QALY, 
well below the stated NICE threshold on £20,000 per QALY. 
 
Venom allergy 
Only one study of moderate quality was found that looked at the economic evaluation of AIT for 
venom.33 This was a modelling study looking at the cost-effectiveness of AIT for the treatment of bee and 
wasp venom allergy (Table 1). The study assessed Pharmalgen venom immunotherapy (PhVIT) + high-
dose anti-histamines (HDA) + adrenaline auto-injector (AAI) versus HDA + AAI and avoidance advice 
only. It found that AIT was not cost-effective in the general population (ICERs of £18 million and £7.6 
million per QALY against HDA + AAI and avoidance advice only, respectively), but more effective than 
other treatment options with the potential for cost saving in patients likely to be stung more than five 
times a year (e.g., bee keepers). A
cc
ep
te
d 
A
rt
ic
le
A
cc
ep
te
d 
A
rt
ic
le
 
 
 
 
 
 
  
 
 
 
 
 
 
This article is protected by copyright. All rights reserved. 
This study, despite the fact that it was based largely on expert opinion and plausible assumptions, 
suggested that AIT for bee and wasp venom allergy was only likely to be cost-effective from an English 
NHS perspective for very high risk groups likely to be exposed to multiple exposures to venom per year. 
The modelling study suggested plausible ranges of exposure to such events to qualify a patient as a 
member of a high risk group and explored a wide range of sensitivity and scenario analyses to 
demonstrate the robustness of its findings.  
 
Food allergy 
We found no studies that met our inclusion criteria that looked at the cost-effectiveness of AIT for food 
allergy. Studies are needed in this area in order to provide information on this rapidly expanding 
treatment area. 
 
Gaps in the literature 
There is significant scope for future well designed studies looking at the cost-effectiveness of AIT for the 
treatment of patients with allergic rhinitis, allergic asthma and IgE-mediated food allergy. However, there 
seems little scope for further research regarding the use of AIT in patients with venom allergy.  Key areas 
that future studies should address include: (1) effectiveness in different populations e.g. children versus 
adults, patients with only allergic rhinitis vs patients with allergic rhinitis and asthma; (2) well conducted 
RCTs with reasonable sample sizes and enough follow-up data to capture treatment effects during and 
after treatment; (3) directly collecting health related quality of life outcomes in the trial using instruments 
such as EQ5D; (4) comparison of the full range of treatment options (i.e.  standard care, SCIT and SLIT) 
from a health system perspective; (5) using methodologically sound analyses to handle missing data and 
selection bias where observational data are used; and (6) fully characterizing the decision uncertainty 
through the use of sensitivity analyses exploring both parameter uncertainty as well as key model 
assumptions such as the duration of treatment effect. A
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DISCUSSION 
Statement of principal finding 
This review has found a limited amount of evidence in relation to the cost-effectiveness of AIT from a 
health system perspective in allergic rhinitis, allergic asthma and venom allergy and no evidence with 
regards to IgE-mediated food allergy. The limited studies identified looking at AIT for the treatment of 
allergic rhinitis suggest that SLIT and SCIT treatment would be considered cost-effective for these 
conditions in England at the standard NICE cost-effectiveness threshold of £20,000 per QALY. 
However, the quality of the studies and the general lack of attention to characterising uncertainty and 
handling missing data should be taken into account when interpreting these results.  
 
Strengths and limitations 
Our search strategies were robust and comprehensive filtering the vast literature pertaining to the subject. 
Furthermore, we actively sought expert opinions to add to the literature in case we had missed studies. 
There is however, always the possibility as with all such overviews, that some studies may not have been 
identified or have slipped through our search processes.  
Studies were conducted in varied patient populations and health care settings, and used a variety of 
outcome measures to assess cost-effectiveness making pooling of results challenging. Where possible 
however, we have used QALYs from an English NHS perspective and converted costs to 2014/15 prices 
in GBP to compare cost-effectiveness results across the studies.  
 
Interpretation in the light of the previous literature 
This is, as far as we are aware, the first economic overview of AIT that has been conducted in relation to 
the conditions under study. 
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Implications for policy, practice and research 
The findings from this overview will be considered together with the related evidence on the effectiveness 
and safety of AIT in drawing up guidelines and developing recommendations for practice. The findings 
from this analysis will be particularly helpful in relation to countries such as the UK and the Netherlands 
that have an explicit focus on health economic evaluations when deciding whether to promote use of 
interventions throughout their health systems.  That said, with increasing pressure on health budgets 
globally the findings from this study are also likely to be of  wider interest. 
This work has also highlighted the need for investigators routinely to consider including formal cost-
effectiveness analyses in their research plans and ensuring that these studies are undertaken to 
international standards.  Consideration also needs to be given to undertaking health economic analyses 
from societal/patient perspectives as the condition can result in a significant personal societal/economic 
burden.  
 
Conclusions 
Overall the evidence to support the cost-effectiveness of AIT is limited and of a low methodological 
quality but appears to suggest that from an English NHS perspective AIT is cost-effective for allergic 
rhinitis, asthma and venom allergy in very high risk subgroups. No studies were identified assessing the 
cost-effectiveness of AIT for treating people with food allergy. There is much scope for further high 
quality studies addressing the methodological gaps identified in this review assessing the cost-
effectiveness of AIT against various allergic conditions. 
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Figure 1: Conceptualization of cost-effectiveness of allergen immunotherapy for allergic 
rhinoconjunctivitis, allergic asthma, food allergy and venom allergy- a systematic overview 
 
 
 
 
 
 
 
 
 
Condition 
• Allergic rhinitis 
 
 
• Allergic asthma 
 
 
• IgE-mediated food 
allergy 
 
 
• Insect venom allergy 
Interventions 
• AIT adminsitered through any route i.e. 
subcutaneous, sublingual, oral, intranasal, 
epicutaneous, intradermal or intra-lymphatic 
• AIT for different allergens (e.g. pollens, mites, animal 
dander, cockroach and mould natural) including 
modified allergens  
 
 
• AIT adminsitered through subcutaneous, or 
sublingual routes 
• AIT for different allergens (e.g. pollens, mites, animal 
dander, cockroach and mould natural)  
 
• AIT administered through  sublingual (SLIT), oral (OIT) 
or epicutaneous (EPIT) routes 
• AIT for different allergens e.g. milk, egg, peanuts and 
tree nuts and other foods 
 
• VIT: subcutaneous immunotherapy (SCIT) and 
sublingual immunotherapy (SLIT) 
• Different products: purified and non-purified 
aqueous, depot  
• Treatment protocols: conventional, cluster, rush 
and ultra-rush 
Outcomes 
• Cost-data 
Study designs 
• Cost-effectiveness or 
cost-utility analysis to 
assess health economics 
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Table 1: Data extraction 
Author, Year 
& Country 
Type of 
Economic 
Analysis 
Perspect
ive 
Study 
Population 
Intervention/
Comparator 
Time 
Horizi
on 
Effectiv
eness 
Data 
Sample 
Size 
Outcome 
Measure 
Outco
me 
Discou
nt 
Rate 
Cost 
Data 
Cost 
year / 
currency 
Cost 
Discount 
Rate 
Results Sensitivity 
Analysis 
General 
Comments 
Rhinitis and asthma studies 
Ariano, 2009, 
Italy13 
CEA Health 
system 
Patients with 
dust mite 
induced 
allergic 
asthma and 
rhinitis 
SLIT / 
Standard Care 
5 years RCT 5 
year 
follow 
up 
70 VAS 
symptom 
score 
0% RCT 
patient 
diary 
and unit 
costs 
?/Euros 0% Overall 
costs lower 
in SLIT 
patients and 
lower 
symptom 
score 
NA Very little detail 
provided of the 
analysis performed     
no real economic 
analysis or 
interpretation of 
the results 
provided 
Nasser, 2008, 
UK14 
CUA Health 
system 
Patients 
suffering 
from grass 
pollen 
induced RC 
co-existing 
with asthma 
SLIT(Grazax)/
Standard care 
9 years RCT 1 
year 
follow-
up 
151 EQ5D - 
QALYs 
3.50% RCT 
patient 
diary 
linked 
to unit 
costs 
2005/G
BP 
3.50% ICER 
£8816 per 
QALY 
One way 
sensitivity 
analysis to 
explore 
impact of 
changing 
time 
horizon 
Results based on 
patients in UK, 
Germany, the 
Netherlands, 
Denmark, Sweden, 
Spain, Austria and 
Italy·                        
Treatment effect 
assumed to persist 
through 3 years of 
treatment and 6 
years following 
treatment 
discontinuation 
Rhinitis with or without asthma 
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Bachert, 
2007, UK, 
Germany, 
Netherlands, 
Sweden, 
Denmark, 
Norway, 
Finland15 
CUA Health 
system 
Patients with 
grass pollen 
induced 
rhinoconjunc
tivitis 
SLIT / 
Standard care 
9 years RCT 1 
year 
follow 
up 
493 EQ5D - 
QALYs 
3 – 5% 
depend
ing on 
country 
RCT 
patient 
diary 
mapped 
to 
country 
specific 
unit 
costs 
2005 / 
Euro 
3 – 5% 
depending 
on country 
Cost per 
year of 
treatment 
must be 
below 2200 
euros for 
SLIT to be 
cost 
effective at 
NICE 
threshold of 
£20000 per 
QALY 
N/A Price of SLIT not 
given so ICERs not 
calculated, rather 
max price for SLIT 
to be cost effective 
calculated  
Treatment effect 
observed in 1 year 
RCT assumed to 
persist through 3 
years of treatment 
and 6 years 
following treatment 
discontinuation 
Berto,2006, 
Italy16 
CEA Health 
system 
Young adults 
with pollen 
induced 
rhinitis with 
or without 
allergic 
asthma 
SLIT / 
Standard care 
6 years Retrospe
ctive 
non-
random 
subset 
selected 
from 
clinical 
study 
2000 Number of 
patients 
improved 
0% Clinical 
records 
linked 
to unit 
costs 
2002 / 
Euro 
3% SLIT is cost 
saving and 
more 
effective 
than 
standard 
care 
Determinist
ic one way 
exploration 
of hospital 
costs 
Potential for 
selection bias as 
physicians asked to 
pick subsets of 
patients from 
clinical study for 
economic 
evaluation 
Bruggenjurge
n, 2008, 
Germany17 
CUA Health 
system 
Patients with 
pollen or 
mite induced 
allergic 
rhinitis with 
or without 
asthma 
SCIT / 
Standard care 
15 years Publishe
d study 
N/A QALYs 3% Publish
ed 
study 
? / Euro 3% ICER SCIT 
vs standard 
care 8308 
euros per 
QALY  
One way 
deterministi
c 
exploration 
od 
alternative 
treatment 
durations 
and 
discount 
rates 
Difficult to assess 
the validity of cost 
or utility data as 
very little detail of 
studies that this 
analysis is based on 
given in the paper 
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Canonica,200
7, Spain, 
Italy, France, 
Austria18 
CUA Societal Patients with 
a 2 year 
history of 
grass pollen 
induced 
allergic 
rhinoconjunc
tivitis with or 
without 
asthma 
SLIT / 
Standard care 
9 years RCT 1 
year 
follow 
up 
Unclear 
subset of 
634 
EQ5D - 
QALYs 
3 – 5 % 
depend
ing on 
country 
RCT 
patient 
diary 
linked 
to unit 
costs 
2004 / 
Euro 
3 – 5 % 
depending 
on country 
0.134 
incremental 
QALYs in 
SLIT 
patients.         
29000 euro 
per QALY 
in all four 
countriesif 
SLIT costs 
1400 euro 
per year 
then ICER 
would be 
less than  
Repeated 
analysis 
excluding 
Spanish 
patients 
Results calculated 
for France even 
though trial did not 
cover France.. 
Unclear exactly 
what data from the 
multi country trial 
was used to 
calculatethese 
results. Treatment 
effect observed in 
1 year RCT 
assumed to persist 
through 3 years of 
treatment and 6 
years following 
treatment 
discontinuation. 
 
 
 
 
 
 
  
 
 
 
 
 
 
This article is protected by copyright. All rights reserved. 
Dranitsaris, 
2014, 
Canada19 
CEA Health 
system 
Patients with 
grass induced 
allergic 
rhinitis with 
or without 
asthma 
SCIT / SLIT 
(GRX) / SLIT 
(OA) / 
Standard care 
1 year Meta-
analysis 
of 20 
RCTs 
N/A Symptom 
control 
0% Expert 
opinion 
2012 / 
CAD 
0%% SCIT, 
SLIT(GRX) 
and SLIT 
(OA) had 
similar 
efficacy in 
terms of 
symptom 
control. 
Cost of 
SCIT = 946 
CAD; Cost 
of SLIT 
(GRX) 
=2122 
CAD; Cost 
of SLIT 
(OA) = 844 
SLIT (OA) 
is as 
effective as 
SLIT 
(GRX) and 
SCIT but 
cheaper 
over 1 year  
N/A Unclear what the 
allergic rhinitis 
symptom score 
represents and if it 
was comparable 
between studies  
Unclear about how 
much of the cost 
data was expert 
opinion as opposed 
to data from the 
meta analysis 
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Keiding 
,2007, UK20 
CUA Health 
system 
Adults with 
clinical 
history of 
grass pollen 
induced 
seasonal 
allergic 
rhinoconjunc
tivitis 
SCIT / 
Standard 
treatment 
9 years RCT 1 
year 
follow 
up 
306 RQLQ 
mapped to 
EQ5D - 
QALYs 
0% Resourc
e use 
collecte
d in 
trial 
with 
national 
unit 
costs 
applied 
2005 / 
Euro 
3%% ICER in 
Euro per 
QALY 
Austria 
9716; 
Denmark 
2586; 
Finland 
13683; 
Germany 
10300; 
Netherlands 
24519; 
Sweden 
22675 
one way 
deterministi
c analysis 
on costs 
described 
but results 
not 
reported 
Treatment effect 
observed in 1 year 
RCT assumed to 
persist through 3 
years of treatment 
and 6 years 
following treatment 
discontinuation. 
Mapping from 
RQLQ to EQ5D 
applied to calculate 
QALYs not 
standard or 
validated 
Meadows,201
3, England21 
CUA Societal Patients with 
pollen 
induced 
allergic 
rhinitis with 
or without 
allergic 
asthma  
SLIT / SCIT / 
Standard care 
6 years Meta-
analysis 
of RCTs 
N/A RQLQ 
mapped to 
EQ5D - 
QALYs 
3.5%% Resourc
e use 
from 
expert 
opinion 
with 
unit 
costs 
applied 
2011 / 
GBP 
3.50% ICER SLIT 
vs standard 
care £37537 
per QALY        
ICER SCIT 
vs standard 
care £29579 
per QALY 
ICER SCIT 
vs SLIT 
£24404 per 
QALY 
N/A Mapping between 
RQLQ and EQ5D 
to calculate QALYs 
not validated 
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Omnes,2007, 
France22 
CEA Health 
system 
Children over 
5 and adults 
over 16 with 
dust mite or 
pollen 
induced 
allergic 
rhinitis 
SLIT / SCIT/ 
Standard care 
7 years 
children
; 6 years 
adults 
Expert 
opinion 
N/A Asthma 
cases 
avoided 
0%% Expert 
opinion 
? / Euro 0%% ICER vs 
standard 
care 
children 
dust mite 
SLIT: 3938; 
SCIT: 583 
ICER vs 
standard 
care 
children 
dust pollen 
SLIT: 824; 
SCIT: 597 
ICER vs 
standard 
care adults 
dust mite 
SLIT: 3158; 
SCIT: 393 
ICER vs 
standard 
care adults 
dust pollen 
SLIT: 1708; 
SCIT: 1327 
All in Euros 
per asthma 
case avo   
N/A Entire study seems 
to be based on 
expert opinion 
Does not compare 
treatment with 
SLIT against SCIT 
incrementally 
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Petersen, 
2005, 
Denmark23 
CEA Societal Patients with 
grass pollen 
or mite 
allergy 
SIT / Standard 
care 
5 years Retrospe
ctive 
question
naire 
following 
trial 
253 Patient year 
of improved 
well being 
5% Admini
strative 
data 
2002 / 
DKK 
5% ICER 2784 
DKK per 
patient year 
of improved 
well being 
N/A Selection bias due 
to partial response 
rate to 
questionnaire not 
controlled for.  
Recall bias not 
controlled for. 
Outcome measure 
is not validated and 
does not capture 
degree of 
improvement.  
Pokladnikova
, 2008, Czech 
Republic24 
CEA Health 
system 
Adults with 
at least 2 
years of 
seasonal 
allergic 
rhinoconjucti
vitis with or 
without 
allergic 
asthma 
SLIT / SCIT / 
Standard Care 
3 years RCT 5 
years 
follow 
up 
19 SLIT, 
23 SCIT, 
22 
Standard 
Care 
RQLQ 0% Admini
strative 
data 
linked 
to unit 
costs 
2002 / 
Euro 
3% SLIT and 
SCIT both 
performed 
better on 
RQLQ than 
standard 
care 
One way 
deterministi
c sensitivity 
analysis 
performed 
on costs 
and 
discount 
rates 
No incremental 
cost effectiveness 
results were 
provided 
Poulsen , 
2008, 
Denmark25 
CUA Health 
system 
Adults with 
grass pollen 
induced 
rhinotconjuct
ivitis 
SLIT / 
Standard care 
9 years RCT one 
year 
follow 
up 
493 EQ5D / 
QALYs 
3%% Unclear ? / DKK 3%% ICER: 
134105 
DKK per 
QALY 
N/A Based on patients 
in Denmark, 
Sweden, England, 
Germany, Holland 
with Danish 
QALY weights and 
unit costs applied 
to EQ5D and 
resource use data. 
Treatment effect 
observed in 1 year 
RCT assumed to 
persist through 3 
years of treatment 
and 6 years 
following treatment 
discontinuation 
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Reinhold, 
2016, 
Germany26 
CEA Health 
system 
29 year old 
patients with 
seasonal 
grass-allergic 
rhinoconjunc
tivitis and no 
asthma 
SLIT (OA) vs 
SCIT 
(Allergovit) vs 
symptomatic 
treatment 
9 years RCT ? Utility 
mapped to 
QALY 
3% Admini
strative 
data 
2013/eur
o 
3% SCIT 
dominates 
SLIT and 
has an 
ICER of 
11000 euros 
per QALY 
against 
symptomati
c treatment 
Probabilistic 
and 
deterministi
c sensitivity 
analysis 
conducted 
This is a model 
based analysis that 
incorporates 
multiple different 
datasets and 
explores a number 
of different 
assumptions in 
sensitivity analysis 
Unexplored 
assumption that 3 
years of treatment 
give continued 
constant treatment 
effect for 9 years 
Ronaldson, 
2014, UK27 
CUA Health 
system 
5-16 year 
olds with 
grass pollen 
induced 
rhinoconjunc
tivitis with or 
without 
asthma 
SLIT / 
Standard care 
9 years RCT 1 
year 
follow 
up 
253 Symptom 
scores 
mapped to 
QALYs 
3.5%% RCT 
Patient 
diaries 
mapped 
to unit 
costs 
2008 / 
GBP 
4% ICER 
£12168 per 
QALY 
PSA 
showed 
90% 
probability 
of SLIT 
being cost 
effective at 
£30000 per 
QALY 
threshold 
and 60% 
probability 
cost 
effective at 
£20000 per 
QALY 
threshold 
 
Mapping from 
symptom scores to 
QALYs not 
validated. 
Treatment effect 
observed in 1 year 
RCT assumed to 
persist through 3 
years of treatment 
and 6 years 
following treatment 
discontinuation 
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Ruggeri, 
2013, Italy28 
CUA Health 
system 
Patients with 
grass pollen 
induced 
allergic 
rhinitis 
SLIT / 
Standard care 
4 years Posthoc 
analysis 
of 2 
RCTs 
? AAdSS 
mapped to 
QALYs 
3% SIMAP 
study 
updated 
to 2011 
2011 / 
Euro 
3%% At low 
AAdSS 
SLIT is 
dominated 
by standard 
care At 
medium 
AAdSS 
ICER 1024 
euros per 
QALY     
At high 
AAdSS 
ICER 1035 
euros per 
QALY  
PSA 
showed 
99% 
probability 
ICER less 
that 30000 
euros per 
QALY for 
medium 
and high 
AAdSS 
Not clear how 
AAdSS is 
converted to 
QALYs.        Cost 
and effectiveness 
estimates taken 
from different 
studies 
Schadlich, 
2000, 
Germany29 
CEA Health 
system 
Patients with 
seasonal 
(pollen) and 
perennial 
(mite) allergy 
with or 
without 
asthma 
SIT / Standard 
Care 
10 years Unclear UC Patients 
who do not 
develop 
asthma 
0% Resourc
e use 
surveys 
1990 / 
DM 
0% SLIT 
performed 
better than 
SCIT and 
was cheaper 
from a 
health 
system 
perspective 
N/A It was very unclear 
what data sources 
were used to 
populate the model 
in this study 
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Verheggen, 
2015, 
Germany30 
CEA Payers 
perspecti
ve 
29 year old 
patients with 
seasonal 
grass-allergic 
rhinoconjunc
tivitis and no 
asthma 
SLIT vs 
blended mix of 
current SCIT 
treatments 
9 years RCT ? QALYs 
mapped 
from 
Rhinitis 
Symptom 
Utility 
Index 
(RSUI) 
3% Admini
strative 
data 
2013/eur
os 
3% ICER of 
SLIT vs 
SCIT is 
12,593 euro 
per QALY 
with a 
probability 
of being 
cost 
effective at 
20,000 euro 
per QALY 
of 76% 
Probabilistic 
and 
deterministi
c sensitivity 
analysis as 
well as 
scenario 
analysis 
performed 
This is a model 
based analysis that 
incorporates 
multiple different 
datasets and 
explores a number 
of different 
assumptions in 
sensitivity analysis 
Comparator is a 
mix of SCIT 
treatments rather 
than one specific 
treatment 
Unexplored 
assumption that 3 
years of treatment 
give continued 
constant treatment 
effect for 9 years 
Westerhout, 
2012, 
Germany31 
CUA Health 
system 
Patients with 
grass pollen 
induced 
rhinoconjunc
tivitis without 
asthma 
SLIT (OA) / 
SLIT (GRZ) / 
SCIT (ALD) / 
Standard care 
9 years Meta-
analysis 
N/A QALYs 3% Survey 
data 
2011 / 
Euro 
3% SLIT (OA) 
dominates 
SLIT 
(GRZ) and 
SCIT (ALD 
).    ICER 
SLIT (OA) 
vs Standard 
care 14728 
euros per 
QALY   
PSA 
suggests 
79% 
probability 
SLIT (OA) 
cost 
effective at 
a threshold 
of £20000 
per QALY 
Treatment effect 
observed in 1 year 
RCT assumed to 
persist through 3 
years of treatment 
and 6 years 
following treatment 
discontinuation•                                                       
Resource use taken 
from external 
survey rather than 
measured in the 
underlying studies 
in meta-analysis 
Asthma only studies 
Reinhold 
,2013, 
Germany26 
CEA Health 
system 
Children and 
adolescents 
with mite 
induced 
allergic 
asthma 
SCIT / 
Standard Care 
3 years RCT 3 
year 
mean 
follow 
up 
65 Mean 
morning 
peak flow 
(l/min) 
0% RCT – 
patient 
diary  
2009 / 
Euro 
0% ICER: 11 
Euros per 
l/min mean 
morning 
peak flow 
Bootstrappi
ng 
performed 
but not 
used in cost 
effectivenes
s results 
No hospital costs 
included  5 SCIT 
and 1 non-SCIT 
patients excluded 
because of 
“outlier” levels of 
costs 
Venom studies 
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Hockenhull, 
2012,England 
CUA Health 
system 
General 
population as 
well as high 
risk of sting 
subset of 
population 
PhVIT + HAD 
+ AAI / HAD 
+ AAI / 
avoidance 
advice only 
10 years Subset of 
RCT and 
survey 
data 
337 Systemic 
reaction or 
death 
following 
sting 
converted 
to QALYs 
3.50% Admini
strative 
data 
and 
referenc
e costs 
? / GBP 3.50% PhVIT + 
HAD + 
AAI is cost 
saving and 
more 
effective 
when 
compared 
to either 
HAD + 
AAI or 
avoidance 
advice only 
for patients 
likely to be 
stung more 
than five 
times a year. 
In the 
general 
population 
the ICER 
for PhVIT 
+ HAD + 
AAI against 
HAD + 
AAI is > 
£18 million 
per QALY 
and against 
avoidance 
advice only 
is > £ 7.6 
million 
 
Extensive 
sensitivity 
analysis on 
wide range 
of model 
parameters 
Very little data 
available to base 
the model on.  
Extensive use of 
sensitivity and 
scenario analysis to 
explore all plausible 
assumption and 
demonstrate the 
robustness of the 
findings 
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Table 2: CASP Economic Evaluation Checklist – Quality 
 
a) Asthma and rhinitis 
Author/year 1.  
Well 
defined 
question 
posed 
2. 
comprehensive 
description of 
competing 
alternatives 
3.  
provides 
evidence of 
effectiveness 
4.  
effects 
identified 
measured 
and valued 
appropriately 
5.  
resource use 
identified 
measured 
and valued 
appropriately 
6.  
discounting 
to adjust for 
timing of 
costs and 
consequences 
7.  
what were 
the results 
8. 
incremental 
analysis 
performed 
9.  
sensitivity 
analysis 
performed 
10. 
effectiveness 
generalisable 
11.  
costs 
generalisable 
Overall 
quality 
L/M/H 
Nasser 2008 Y Y Y Y Y Y SLIT ICER 
£8816 (2005) 
per QALY 
Y N Y Y H 
Ariano 2009 Y Y N N N N Lower cost 
and 
symptom 
score with 
SLIT 
N N N N L 
 
b) Rhinitis with or without asthma 
Author/year 1.  
Well 
defined 
questio
n posed 
2. 
comprehensiv
e description 
of competing 
alternatives 
3.  
provides 
evidence of 
effectivenes
s 
4.  
effects 
identified 
measured 
and valued 
appropriatel
y 
5.  
resource use 
identified 
measured 
and valued 
appropriatel
y 
6.  
discounting 
to adjust for 
timing of 
costs and 
consequenc
es 
7.  
what were the 
results 
8. 
incremen
tal 
analysis 
performe
d 
9.  
sensitivity 
analysis 
performed 
10. 
effectivenes
s 
generalisabl
e 
11.  
costs 
generalisabl
e 
Overall 
quality 
L/M/H 
Schadlich 2000 Y Y N N N N SIT is cost saving 
and reduces 
chances of 
developing 
asthma 
N N N N L 
Pokladnikova 
2008 
Y Y Y Y Y Y SLIT costs less 
that SCIT with 
similar 
effectiveness 
N N N Y L 
Peterson 2005 Y Y Y N Y Y SIT ICER 2784 
DKK per patient 
year of improved 
well being 
Y N N Y M 
Poulson 2008 Y Y Y Y Y Y ICER SCIT 
134105 KR per 
QALY 
Y N Y N M 
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Author/year 1.  
Well 
defined 
questio
n posed 
2. 
comprehensiv
e description 
of competing 
alternatives 
3.  
provides 
evidence of 
effectivenes
s 
4.  
effects 
identified 
measured 
and valued 
appropriatel
y 
5.  
resource use 
identified 
measured 
and valued 
appropriatel
y 
6.  
discounting 
to adjust for 
timing of 
costs and 
consequenc
es 
7.  
what were the 
results 
8. 
incremen
tal 
analysis 
performe
d 
9.  
sensitivity 
analysis 
performed 
10. 
effectivenes
s 
generalisabl
e 
11.  
costs 
generalisabl
e 
Overall 
quality 
L/M/H 
Canonica 2007 Y Y N N N Y SLIT ICER < 
29000 Euros per 
QALY when 
annual cost of 
treatment < 1400 
euro 
Y N N N L 
Keiding 2007 Y Y Y N Y N SLIT ICER 9716 
to 14519 euros 
(2005) per 
QALY 
Y N Y Y M 
Rugerri 2013 Y Y Y N N Y SLIT ICER 1035 
euros per QALY  
Y Y N N L 
Ronaldson 2014 Y Y Y Y Y Y SCIT £12168 
(2008) per 
QALY 
Y Y Y Y H 
Bachert 2007 Y Y Y Y N Y SLIT ICER less 
than £20000 per 
QALY if 
treatment cost < 
2200 euro per 
year 
Y N Y Y M 
Westerhout 2012 Y Y Y Y N Y SLIT (OA) ICER 
14728 euro per 
QALY 
Y Y Y N M 
Berto 2006 Y Y N N N N SLIT cost saving 
and more 
effective than 
standard care 
Y N N N L 
Meadows 2013 Y Y Y N N Y ICER SCIT vs 
ST £29579 per 
QALY 
SCIT vs SLIT 
£24404 per 
QALY   
Y N Y Y M 
Omnes 2007 Y Y N N N N ICERs euros per 
asthma cases 
avoided under 
3983 for SLIT 
and under 1327 
for SCIT in all 
subgroups  
N N N N L 
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Author/year 1.  
Well 
defined 
questio
n posed 
2. 
comprehensiv
e description 
of competing 
alternatives 
3.  
provides 
evidence of 
effectivenes
s 
4.  
effects 
identified 
measured 
and valued 
appropriatel
y 
5.  
resource use 
identified 
measured 
and valued 
appropriatel
y 
6.  
discounting 
to adjust for 
timing of 
costs and 
consequenc
es 
7.  
what were the 
results 
8. 
incremen
tal 
analysis 
performe
d 
9.  
sensitivity 
analysis 
performed 
10. 
effectivenes
s 
generalisabl
e 
11.  
costs 
generalisabl
e 
Overall 
quality 
L/M/H 
Bruggenjurgen 
2008 
Y Y N N N Y ICER SCIT 8303 
euro per QALY 
Y N N N L 
Dranitsaris  2014 Y Y Y N Y N SLIT (OA) 
cheaper than 
SLIT (GRX) and 
SCIT and 
similarly effective 
in terms of 
symptom control 
N N N Y L 
Reinhold 2016 Y Y Y Y Y Y SCIT (Allergovit) 
cheaper & more 
effective than 
SLIT (OA). 
ICER for SCIT 
against 
symptomatic 
treatment was 
11000 euros per 
QALY  
Y Y Y N H 
Verheggen 
2015 
Y Y Y Y Y Y SLIT (OA) more 
costly & effective 
than SCIT. ICER 
of 12593 per 
QALY & 76% 
chance of being 
cost-effective at 
threshold of 
20000 euro  
Y Y N N H 
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c) Asthma only studies 
Author
/year 
1.  
Well 
defin
ed 
ques
tion 
pose
d 
2. 
compreh
ensive 
descripti
on of 
competi
ng 
alternati
ves 
3.  
provide
s 
evidenc
e of 
effectiv
eness 
4.  
effects 
identifi
ed 
measur
ed and 
valued 
appropr
iately 
5.  
resourc
e use 
identifi
ed 
measur
ed and 
valued 
appropr
iately 
6.  
discoun
ting to 
adjust 
for 
timing 
of costs 
and 
consequ
ences 
7.  
wha
t 
were 
the 
resul
ts 
8. 
increm
ental 
analysi
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Appendix 1: Data extraction forms 
Rhinitis and asthma 
Title: Cost effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with 
asthma 
Author / Year: Nasser / 200814 
Journal: Allergy 
Type of economic analysis Perspective Countries 
CUA Health system UK 
Study population 
Patients suffering from grass pollen induced rhinoconjunctivitis co-existing with asthma 
Intervention / Comparator Time horizon Effectiveness data 
SLIT (Grazax) / Standard Care 9 years RCT 1 year follow up 
Sample size Outcome measure Outcome discount rate 
151 EQ5D - QALYs 3.5% 
Cost data Cost year / currency Cost discount rate 
RCT patient diary linked to unit 
costs 
2005 / GBP 3.5% 
Results Sensitivity analysis 
ICER £8816 per QALY One way sensitivity analysis to 
explore impact of changing 
time horizon 
 
General comments 
 
 results based on patients in UK, Germany, the Netherlands, Denmark, Sweden, Spain, 
Austria and Italy 
 treatment effect assumed to persist through 3 years of treatment and 6 years following 
treatment discontinuation 
 
 
 A
cc
ep
te
d 
A
rt
ic
le
A
cc
ep
te
d 
A
rt
ic
le
 
 
 
 
 
 
  
 
 
 
 
 
 
This article is protected by copyright. All rights reserved. 
Title: Economic evaluation of sublingual immunotherapy vs symptomatic treatment in allergic 
asthma 
Author / Year: Ariano / 200913 
Journal: Annals of Allergy, Asthma & Immunology 
Type of economic analysis Perspective Countries 
CEA Health system Italy 
Study population 
Patients with dust mite induced allergic asthma and rhinitis 
Intervention / Comparator Time horizon Effectiveness data 
SLIT / Standard Care 5 years RCT 5 year follow up 
Sample size Outcome measure Outcome discount rate 
70 VAS symptom score 0% 
Cost data Cost year / currency Cost discount rate 
RCT patient diary and unit 
costs 
? / Euros 0% 
Results Sensitivity analysis 
Overall costs lower in SLIT patients and lower symptom score NA 
 
General comments 
 
 very little detail provided of the analysis performed 
 no real economic analysis or interpretation of the results provided 
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Data extraction of Rhinitis with or without Asthma studies 
Title: Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic 
rhinitis in Germany 
Author / Year: Schadlich / 200029 
Journal: Pharmacoeconomics 
Type of economic analysis Perspective Countries 
CEA Health System Germany 
Study population 
Patients with seasonal (pollen) and perennial (mite) allergy with or without asthma 
Intervention / Comparator Time horizon Effectiveness data 
SIT / Standard Care 10 years Unclear 
Sample size Outcome measure Outcome discount rate 
- Patients who do not develop 
asthma 
0% 
Cost data Cost year / currency Cost discount rate 
Resource use surveys 1990 / DM 0% 
Results Sensitivity analysis 
SIT was found to be cost saving as compared to standard care 
and reduced the chances of patients developing asthma 
NA 
 
General comments 
 It was very unclear what data sources were used to populate the model in this study 
 
 
 
 A
cc
ep
te
d 
A
rt
ic
le
A
cc
ep
te
d 
A
rt
ic
le
 
 
 
 
 
 
  
 
 
 
 
 
 
This article is protected by copyright. All rights reserved. 
Title: Economic evaluation of sublingual vs subcutaneous allergen immunotherapy 
Author / Year: Pokladnikova / 200824 
Journal: Annals of Allergy, Asthma & Immunology 
Type of economic analysis Perspective Countries 
CEA Health system Czech Republic 
Study population 
Adults with at least 2 years of seasonal allergic rhinoconjuctivitis with or without allergic asthma 
Intervention / Comparator Time horizon Effectiveness data 
SLIT / SCIT / Standard Care 3 years RCT 5 years follow up 
Sample size Outcome measure Outcome discount rate 
19 SLIT, 23 SCIT, 22 Standard 
Care 
RQLQ 0% 
Cost data Cost year / currency Cost discount rate 
Administrative data linked to 
unit costs 
2002 / Euro 3% 
Results Sensitivity analysis 
SLIT and SCIT both performed better on RQLQ than standard 
care 
SLIT performed better than SCIT and was cheaper from a health 
system perspective 
One way deterministic 
sensitivity analysis performed 
on costs and discount rates 
 
General comments 
 
 No incremental cost effectiveness results were provided 
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Title: Health economic analysis of subcutaneous specific immunotherapy for grass pollen and mite 
allergy 
Author / Year: Petersen / 200523 
Journal: Allergol et Immunopathol 
Type of economic analysis Perspective Countries 
CEA Societal Denmark 
Study population 
Patients with grass pollen or mite allergy 
Intervention / Comparator Time horizon Effectiveness data 
SIT / Standard care 5 years Retrospective questionnaire 
following trial 
Sample size Outcome measure Outcome discount rate 
253 Patient year of improved well 
being 
5% 
Cost data Cost year / currency Cost discount rate 
Administrative data 2002 / DKK 5% 
Results Sensitivity analysis 
ICER 2784 DKK per patient year of improved well being NA 
General comments 
 Selection bias due to partial response rate to questionnaire not controlled for 
 Recall bias not controlled for 
 Outcome measure is not validated and does not capture degree of improvement 
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Title: Economic evaluation of a tablet based vaccination against hay fever in Denmark 
Author / Year: Poulsen / 200825 
Journal: Ugeskr Laeger 
Type of economic analysis Perspective Countries 
CUA Health system Denmark 
Study population 
Adults with grass pollen induced rhinotconjuctivitis 
Intervention / Comparator Time horizon Effectiveness data 
SLIT / Standard care 9 years RCT one year follow up 
Sample size Outcome measure Outcome discount rate 
493 EQ5D / QALYs 3% 
Cost data Cost year / currency Cost discount rate 
Unclear ? / DKK 3% 
Results Sensitivity analysis 
ICER: 134105 DKK per QALY NA 
 
General comments 
 Based on patients in Denmark, Sweden, England, Germany, Holland with Danish QALY 
weights and unit costs applied to EQ5D and resource use data 
 Treatment effect observed in 1 year RCT assumed to persist through 3 years of treatment 
and 6 years following treatment discontinuation 
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Title: Cost effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in 
Southern Europe 
Author / Year: Canonica / 200718 
Journal: Respiratory Medicine 
Type of economic analysis Perspective Countries 
CUA Societal Spain, Italy, France, Austria 
Study population 
Patients with a 2 year history of grass pollen induced allergic rhinoconjunctivitis with or without 
asthma 
Intervention / Comparator Time horizon Effectiveness data 
SLIT / Standard care 9 years RCT 1 year follow up 
Sample size Outcome measure Outcome discount rate 
Unclear subset of 634 EQ5D - QALYs 3 – 5 % depending on country 
Cost data Cost year / currency Cost discount rate 
RCT patient diary linked to unit 
costs 
2004 / Euro 3 – 5 % depending on country 
Results Sensitivity analysis 
0.134 incremental QALYs in SLIT patients 
if SLIT costs 1400 euro per year then ICER would be less than 
29000 euro per QALY in all four countries 
Repeated analysis excluding 
Spanish patients  
 
General comments 
 Results calculated for France even though trial did not cover France 
 Unclear exactly what data from the multi country trial was used to calculate these results 
 Treatment effect observed in 1 year RCT assumed to persist through 3 years of treatment 
and 6 years following treatment discontinuation 
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Title: A cost effectiveness analysis of immunotherapy with SQ allergen extract for patients with 
seasonal allergic rhinoconjunctivitis in selected European countries 
Author / Year: Keiding / 200720 
Journal:  Current Medical Research and Opinions 
Type of economic analysis Perspective Countries 
CUA Health system Austria, Denmark, Finland, 
Germany, Netherlands, 
Sweden 
Study population 
Adults with clinical history of grass pollen induced seasonal allergic rhinoconjunctivitis 
Intervention / Comparator Time horizon Effectiveness data 
SCIT / Standard treatment 9 years RCT 1 year follow up 
Sample size Outcome measure Outcome discount rate 
306 RQLQ mapped to EQ5D - 
QALYs 
0% 
Cost data Cost year / currency Cost discount rate 
Resource use collected in trial 
with national unit costs 
applied 
2005 / Euro 3% 
Results Sensitivity analysis 
ICER in Euro per QALY 
Austria 9716; Denmark 2586; Finland 13683; Germany 10300; 
Netherlands 24519; Sweden 22675 
One way deterministic analysis 
on costs described but results 
not reported 
General comments 
 Treatment effect observed in 1 year RCT assumed to persist through 3 years of treatment 
and 6 years following treatment discontinuation 
 Mapping from RQLQ to EQ5D applied to calculate QALYs not standard or validated 
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Title: Economic evaluation of 5-grass pollen tablets versus placebo in the treatment of allergic 
rhinitis in adults 
Author / Year: Ruggeri / 201328 
Journal: Clinical Drug Investigation 
Type of economic analysis Perspective Countries 
CUA Health system Italy 
Study population 
Patients with grass pollen induced allergic rhinitis 
Intervention / Comparator Time horizon Effectiveness data 
SLIT / Standard care 4 years Posthoc analysis of 2 RCTs 
Sample size Outcome measure Outcome discount rate 
? AAdSS mapped to QALYs 3% 
Cost data Cost year / currency Cost discount rate 
SIMAP study updated to 2011 2011 / Euro 3% 
Results Sensitivity analysis 
At low AAdSS SLIT is dominated by standard care 
At medium AAdSS ICER 1024 euros per QALY 
At high AAdSS ICER 1035 euros per QALY  
PSA showed 99% probability 
ICER less that 30000 euros per 
QALY for medium and high 
AAdSS 
General comments 
 Not clear how AAdSS is converted to QALYs 
 Cost and effectiveness estimates taken from different studies 
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Title: Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (GRAZAX) in 
children 
Author / Year: Ronaldson / 201427 
Journal: ClinicoEconomics and Outcomes Research 
Type of economic analysis Perspective Countries 
CUA Health system UK 
Study population 
5-16 year olds with grass pollen induced rhinoconjunctivitis with or without asthma 
Intervention / Comparator Time horizon Effectiveness data 
SLIT / Standard care 9 years RCT 1 year follow up 
Sample size Outcome measure Outcome discount rate 
253  Symptom scores mapped to 
QALYs 
3.5% 
Cost data Cost year / currency Cost discount rate 
RCT Patient diaries mapped to 
unit costs 
2008 / GBP 3.5% 
Results Sensitivity analysis 
ICER £12168 per QALY PSA showed 90% probability of 
SLIT being cost effective at 
£30000 per QALY threshold 
and 60% probability cost 
effective at £20000 per QALY 
threshold 
General comments 
 Mapping from symptom scores to QALYs not validated 
 Treatment effect observed in 1 year RCT assumed to persist through 3 years of treatment 
and 6 years following treatment discontinuation 
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Title: Cost effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen 
induced rhinoconjunctivitis – a Northern European perspective 
Author / Year: Bachert / 200715 
Journal: Clinical and Experimental Allergy 
Type of economic analysis Perspective Countries 
CUA Health system UK, Germany, Netherlands, 
Sweden, Denmark, Norway, 
Finland 
Study population 
Patients with grass pollen induced rhinoconjunctivitis 
Intervention / Comparator Time horizon Effectiveness data 
SLIT / Standard care 9 years RCT 1 year follow up 
Sample size Outcome measure Outcome discount rate 
493 EQ5D - QALYs 3 – 5% depending on country 
Cost data Cost year / currency Cost discount rate 
RCT patient diary mapped to 
country specific unit costs 
2005 / Euro 3 – 5% depending on country 
Results Sensitivity analysis 
Cost per year of treatment must be below 2200 euros for SLIT to 
be cost effective at NICE threshold of £20000 per QALY 
NA 
General comments 
 
 Price of SLIT not given so ICERs not calculated, rather max price for SLIT to be cost 
effective calculated 
 Treatment effect observed in 1 year RCT assumed to persist through 3 years of treatment 
and 6 years following treatment discontinuation 
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Title: Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic 
rhinoconjuntivitis in Germany 
Author / Year: Westerhout / 201231 
Journal: Journal of Medical Economics 
Type of economic analysis Perspective Countries 
CUA Health system Germany 
Study population 
Patients with grass pollen induced rhinoconjunctivitis without asthma 
Intervention / Comparator Time horizon Effectiveness data 
SLIT (OA) / SLIT (GRZ) / SCIT 
(ALD) / Standard care 
9 years Meta-analysis 
Sample size Outcome measure Outcome discount rate 
NA QALYs 3% 
Cost data Cost year / currency Cost discount rate 
Survey data 2011 / Euro 3% 
Results Sensitivity analysis 
SLIT (OA) dominates SLIT (GRZ) and SCIT (ALD) 
ICER SLIT (OA) vs Standard care 14728 euros per QALY 
PSA suggests 79% probability 
SLIT (OA) cost effective at a 
threshold of £20000 per QALY 
General comments 
 Treatment effect observed in 1 year RCT assumed to persist through 3 years of treatment 
and 6 years following treatment discontinuation 
 Resource use taken from external survey rather than measured in the underlying studies 
in meta analysis 
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Title: Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with 
pollen induced respiratory allergy: the sublingual immunotherapy pollen allergy Italy (SPAI) study 
Author / Year: Berto / 200616 
Journal: Annals of Allergy, Asthma and Immunology 
Type of economic analysis Perspective Countries 
CEA Health system Italy 
Study population 
Young adults with pollen induced rhinitis with or without allergic asthma 
Intervention / Comparator Time horizon Effectiveness data 
SLIT / Standard care 6 years Retrospective non-random 
subset selected from clinical 
study 
Sample size Outcome measure Outcome discount rate 
2000 Number of patients improved 0% 
Cost data Cost year / currency Cost discount rate 
Clinical records linked to unit 
costs 
2002 / Euro 3% 
Results Sensitivity analysis 
SLIT is cost saving and more effective than standard care Deterministic one way 
exploration of hospital costs 
General comments 
 Potential for selection bias as physicians asked to pick subsets of patients from clinical 
study for economic evaluation 
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Title: A systematic review and economic evaluation of subcutaneous and sublingual allergen 
immunotherapy in adults and children with seasonal allergic rhinitis 
Author / Year: Meadows / 201321 
Journal: NIHR Health Technology Assessment 
Type of economic analysis Perspective Countries 
CUA Societal England 
Study population 
Patients with pollen induced allergic rhinitis with or without allergic asthma  
Intervention / Comparator Time horizon Effectiveness data 
SLIT / SCIT / Standard care 6 years Meta analysis of RCTs 
Sample size Outcome measure Outcome discount rate 
NA RQLQ mapped to EQ5D - 
QALYs 
3.5% 
Cost data Cost year / currency Cost discount rate 
Resource use from expert 
opinion with unit costs applied 
2011 / GBP 3.5% 
Results Sensitivity analysis 
ICER SLIT vs standard care £37537 per QALY 
ICER SCIT vs standard care £29579 per QALY 
ICER SCIT vs SLIT £24404 per QALY 
NA 
General comments 
 Mapping between RQLQ and EQ5D to calculate QALYs not validated 
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Title: Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic 
treatment for allergic rhinitis and asthma in France 
Author / Year: Omnes / 200722 
Journal: European Annals of Allergy and Clinical Immunology 
Type of economic analysis Perspective Countries 
CEA Health system France 
Study population 
Children over 5 and adults over 16 with dust mite or pollen induced allergic rhinitis 
Intervention / Comparator Time horizon Effectiveness data 
SLIT / SCIT/ Standard care 7 years children; 6 years adults Expert opinion 
Sample size Outcome measure Outcome discount rate 
NA Asthma cases avoided 0% 
Cost data Cost year / currency Cost discount rate 
Expert opinion ? / Euro 0% 
Results Sensitivity analysis 
ICER vs standard care children dust mite SLIT: 3938; SCIT: 583 
ICER vs standard care children dust pollen SLIT: 824; SCIT: 597 
ICER vs standard care adults dust mite SLIT: 3158; SCIT: 393 
ICER vs standard care adults dust pollen SLIT: 1708; SCIT: 1327 
All in Euros per asthma case avoided 
NA 
General comments 
 Entire study seems to be based on expert opinion 
 Does not compare treatment with SLIT against SCIT incrementally 
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Title: Cost effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis 
and allergic asthma 
Author / Year: Bruggenjurgen / 200817 
Journal: Annals of Allergy, Asthma & Immunology 
Type of economic analysis Perspective Countries 
CUA Health system Germany 
Study population 
Patients with pollen or mite induced allergic rhinitis with or without asthma 
Intervention / Comparator Time horizon Effectiveness data 
SCIT / Standard care 15 years Published study 
Sample size Outcome measure Outcome discount rate 
NA QALYs 3% 
Cost data Cost year / currency Cost discount rate 
Published study ? / Euro 3% 
Results Sensitivity analysis 
ICER SCIT vs standard care 8308 euros per QALY  One way deterministic 
exploration od alternative 
treatment durations and 
discount rates 
General comments 
 Difficult to assess the validity of cost or utility data as very little detail of studies that this 
analysis is based on given in the paper 
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Title: Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of 
efficacy, safety and cost 
Author / Year: Dranitsaris / 201419 
Journal: Journal of Evaluation in Clinical Practice 
Type of economic analysis Perspective Countries 
CEA Health system Canada 
Study population 
Patients with grass induced allergic rhinitis with or without asthma 
Intervention / Comparator Time horizon Effectiveness data 
SCIT / SLIT (GRX) / SLIT (OA) / 
Standard care 
1 year Meta analysis of 20 RCTs 
Sample size Outcome measure Outcome discount rate 
NA Symptom control 0% 
Cost data Cost year / currency Cost discount rate 
Expert opinion 2012 / CAD 0% 
Results Sensitivity analysis 
SCIT, SLIT(GRX) and SLIT (OA) had similar efficacy in terms of 
symptom control. Cost of SCIT = 946 CAD; Cost of SLIT (GRX) = 
2122 CAD; Cost of SLIT (OA) = 844 
SLIT (OA) is as effective as SLIT (GRX) and SCIT but cheaper over 
1 year 
NA 
General comments 
 Unclear what the allergic rhinitis symptom score represents and if it was comparable 
between studies 
 Unclear about how much of the cost data was expert opinion as opposed to data from the 
meta analysis 
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Title: Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment 
Author / Year: Reinhold / 201626 
Journal: Allergo Journal International 
Type of economic analysis Perspective Countries 
CEA Health insurer Germany 
Study population 
29 year old patients with seasonal grass-allergic rhinoconjunctivitis and no asthma 
Intervention / Comparator Time horizon Effectiveness data 
SLIT (OA) vs SCIT (Allergovit) vs 
symptomatic treatment 
9 years RCT 
Sample size Outcome measure Outcome discount rate 
? Utility mapped to QALY 3% 
Cost data Cost year / currency Cost discount rate 
Administrative data 2013/euro 3% 
Results Sensitivity analysis 
SCIT dominates SLIT and has an ICER of 11000 euros per QALY 
against symptomatic treatment 
Probabilistic and deterministic 
sensitivity analysis conducted 
General comments 
 This is a model based analysis that incorporates multiple different datasets and explores a 
number of different assumptions in sensitivity analysis 
 Unexplored assumption that 3 years of treatment give continued constant treatment 
effect for 9 years 
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Title: Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients 
with seasonal grass-allergic rhinoconjunctivitis in Germany 
Author / Year: Verheggen / 201530 
Journal: Clinical and Translational Allergy 
Type of economic analysis Perspective Countries 
CEA Payer’s perspective Germany 
Study population 
29 year old patients with seasonal grass-allergic rhinoconjunctivitis and no asthma 
Intervention / Comparator Time horizon Effectiveness data 
SLIT vs blended mix of current 
SCIT treatments 
9 years RCT 
Sample size Outcome measure Outcome discount rate 
? QALYs mapped from Rhinitis 
Symptom Utility Index (RSUI) 
3% 
Cost data Cost year / currency Cost discount rate 
Administrative data 2013/euros 3% 
Results Sensitivity analysis 
ICER of SLIT vs SCIT is 12,593 euro per QALY with a probability of 
being cost effective at 20,000 euro per QALY of 76% 
Probabilistic and deterministic 
sensitivity analysis as well as 
scenario analysis performed 
General comments 
 This is a model based analysis that incorporates multiple different datasets and explores a 
number of different assumptions in sensitivity analysis 
 Comparator is a mix of SCIT treatments rather than one specific treatment 
 Unexplored assumption that 3 years of treatment give continued constant treatment 
effect for 9 years 
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Data extraction of Asthma studies 
Title: Influence of subcutaneous specific immunotherapy on drug costs in children suffering from 
allergic asthma 
Author / Year: Reinhold / 201332 
Journal: Clinical and Translational Allergy 
Type of economic analysis Perspective Countries 
CEA Health system Germany 
Study population 
Children and adolescents with mite induced allergic asthma 
Intervention / Comparator Time horizon Effectiveness data 
SCIT / Standard Care 3 years RCT 3 year mean follow up 
Sample size Outcome measure Outcome discount rate 
65 Mean morning peak flow 
(l/min) 
0% 
Cost data Cost year / currency Cost discount rate 
RCT – patient diary  2009 / Euro 0% 
Results Sensitivity analysis 
ICER: 11 Euros per l/min mean morning peak flow Bootstrapping performed but 
not used in cost effectiveness 
results 
 
General comments 
 No hospital costs included 
 5 SCIT and 1 non-SCIT patients excluded because of “outlier” levels of costs 
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Data extraction of Asthma and Rhinitis studies 
Title: Cost effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with 
asthma 
Author / Year: Nasser / 200814 
Journal: Allergy 
Type of economic analysis Perspective Countries 
CUA Health system UK 
Study population 
Patients suffering from grass pollen induced rhinoconjunctivitis co-existing with asthma 
Intervention / Comparator Time horizon Effectiveness data 
SLIT (Grazax) / Standard Care 9 years RCT 1 year follow up 
Sample size Outcome measure Outcome discount rate 
151 EQ5D - QALYs 3.5% 
Cost data Cost year / currency Cost discount rate 
RCT patient diary linked to unit 
costs 
2005 / GBP 3.5% 
Results Sensitivity analysis 
ICER £8816 per QALY One way sensitivity analysis to 
explore impact of changing 
time horizon 
 
General comments 
 
 results based on patients in UK, Germany, the Netherlands, Denmark, Sweden, Spain, 
Austria and Italy 
 treatment effect assumed to persist through 3 years of treatment and 6 years following 
treatment discontinuation 
 
 
 
Title: Economic evaluation of sublingual immunotherapy vs symptomatic treatment in allergic 
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Author / Year: Ariano / 200913 
Journal: Annals of Allergy, Asthma & Immunology 
Type of economic analysis Perspective Countries 
CEA Health system Italy 
Study population 
Patients with dust mite induced allergic asthma and rhinitis 
Intervention / Comparator Time horizon Effectiveness data 
SLIT / Standard Care 5 years RCT 5 year follow up 
Sample size Outcome measure Outcome discount rate 
70 VAS symptom score 0% 
Cost data Cost year / currency Cost discount rate 
RCT patient diary and unit 
costs 
? / Euros 0% 
Results Sensitivity analysis 
Overall costs lower in SLIT patients and lower symptom score NA 
 
General comments 
 
 very little detail provided of the analysis performed 
 no real economic analysis or interpretation of the results provided 
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Data extraction of Insect Venom Allergy study 
Title: A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the 
treatment of bee and wasp venom allergy 
Author / Year: Hockenhull / 201233 
Journal: NIHR HTA 
Type of economic analysis Perspective Countries 
CUA Health System England 
Study population 
General population as well as high risk of sting subset of population 
Intervention / Comparator Time horizon Effectiveness data 
PhVIT + HAD + AAI / HAD + AAI 
/ avoidance advice only 
10 years Subset of RCT and survey data 
Sample size Outcome measure Outcome discount rate 
337 Systemic reaction or death 
following sting converted to 
QALYs 
3.5% 
Cost data Cost year / currency Cost discount rate 
Administrative data and 
reference costs 
? / GBP 3.5% 
Results Sensitivity analysis 
PhVIT + HAD + AAI is cost saving and more effective when 
compared to either HAD + AAI or avoidance advice only for 
patients likely to be stung more than five times a year. 
In the general population the ICER for PhVIT + HAD + AAI against 
HAD + AAI is > £18 million per QALY and against avoidance 
advice only is > £ 7.6 million 
Extensive sensitivity analysis 
on wide range of model 
parameters 
General comments 
 Very little data available to base the model on 
 Extensive use of sensitivity and scenario analysis to explore all plausible assumption and 
demonstrate the robustness of the findings 
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Appendix 2: PRISMA Checklist 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
4/5 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
4/5/6 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
4/5 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
4/5/6 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
4/5/6 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
4/5/6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
5/6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
4/5/6 
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Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
5 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  5/6 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
5/6 
 
Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
5 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
6 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
Table 1, 
15-24 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Table2a-
e 25-29 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
7-11 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Table 2 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  N/A 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
12 
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Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
12/13 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  12/13 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
13 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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